Efficacy, safety, and tolerability of seladelpar in patients with compensated liver cirrhosis due to primary biliary cholangitis (PBC): a pooled analysis of phase 2 and phase 3 studies

Authors

Stuart C. Gordon, Henry Ford HealthFollow
Palak Trivedi
Christopher Bowlus
Galambos Michael
Aparna Goel
Aliya Gulamhusein
Cynthia Levy
Guy Neff
Carmen Stanca
Douglas Thorburn
Bruce Bacon
Brian Borg
Yvonne Doerffel
Lisa Forman
Bradley Freilich
Liana Gheorghe
María S. González
Stephen Harrison
Jonathan Huang
Sook-Hyang Jeong
Seung U. Kim
John Lake
Joseph Odin
Won Y. Tak
Hillel Tobias
John M. Vierling
Ke Yang
Alexandra Steinberg
Yun-Jung Choi
Charles McWherter
Marlyn J. Mayo

Recommended Citation

Gordon SC, Trivedi P, Bowlus C, Michael G, Goel A, Gulamhusein A, Levy C, Neff G, Stanca C, Thorburn D, Bacon B, Borg B, Doerffel Y, Forman L, Freilich B, Gheorghe L, Gonzalez MS, Harrison S, Huang J, Jeong S-H, Kim SU, Lake J, Odin J, Tak WY, Tobias H, Vierling JM, Yang K, Steinberg A, Choi Y-J, McWherter C, and Mayo MJ. Efficacy, safety, and tolerability of seladelpar in patients with compensated liver cirrhosis due to primary biliary cholangitis (PBC): a pooled analysis of phase 2 and phase 3 studies. J Hepatol 2021; 75:S686-S687.

Document Type

Conference Proceeding

Publication Date

7-1-2021

Publication Title

J Hepatol

Volume

75

Issue

Suppl 2

First Page

S686

Last Page

S687